SWOG clinical trial number
CTSU/E3108
A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
Closed
Phase
Abbreviated Title
Phase II Metastatic Breast CYP2D6 Activity
Status Notes
This protocol is permanently closed to accrual effective 10/22/15.
Activated
11/15/2010
Closed
10/22/2015
Participants
CTSU
Research committees
Breast Cancer
Treatment
Tamoxifen
Eligibility Criteria Expand/Collapse
SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly either by phon (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly either by phon (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
3%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase